Davita Inc. Stock
Davita Inc. Stock
Davita Inc. dominated the market today, gaining €4.15 (3.330%).
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the Davita Inc. stock is not clear.
However, we have a potential of -3.8% for Davita Inc. as the target price of 124 € is below the current price of 128.9 €.
For the coming years our community has positive and negative things to say abot the Davita Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Davita Inc. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Davita Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Davita Inc. | 3.330% | 3.576% | 0.782% | 57.157% | 36.518% | 37.537% | 153.242% |
| Amn Healthcare Svs | 2.860% | 0.962% | -7.895% | -32.258% | -21.642% | -21.642% | 14.742% |
| Chemed Corp. | -2.830% | -4.505% | -10.169% | 9.053% | 1.923% | 38.021% | 79.327% |
| Select Medical Holdings | 0.780% | 0.000% | -7.246% | -5.185% | 18.519% | -19.497% | 97.897% |
Comments
DaVita Inc. (NYSE: DVA) had its price target raised by analysts at UBS Group AG from $113.00 to $134.00. They now have a "buy" rating on the stock.
Show more
Ratings data for DVA provided by MarketBeat
DaVita Inc. (NYSE: DVA) had its price target lowered by analysts at UBS Group AG from $142.00 to $113.00. They now have a "buy" rating on the stock.
Show more
Ratings data for DVA provided by MarketBeat